par Bertini, Enrico;Dessaud, Eric;Mercuri, Eugenio;Muntoni, Francesco;Kirschner, Janbernd;Reid, Carol;Lusakowska, Anna;Deconinck, Nicolas ;Cuisset, Jean Marie;Abitbol, Jean-Louis;Scherrer, Bruno;Ducray, Patricia Sanwald;Buchbjerg, Jeppe;Vianna, Eduardo;van der Pol, Ludo WL;Vuillerot, Carole;Blaettler, Thomas;Fontoura, Paulo;Olesoxime SMA Phase 2 Study Investigators,
Référence Lancet neurology, 16, 7, page (513-522)
Publication Publié, 2017-07
Référence Lancet neurology, 16, 7, page (513-522)
Publication Publié, 2017-07
Article révisé par les pairs
Résumé : | Spinal muscular atrophy (SMA) is a progressive motor neuron disease causing loss of motor function and reduced life expectancy, for which limited treatment is available. We investigated the safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 SMA. |